Efficacy and safety of risankizumab in patients with psoriasis showing suboptimal response to secukinumab or ixekizumab: Results from a phase 3b, open-label, single-arm (aIMM) study
media
posted on 2024-10-22, 13:24 authored by Adis journals on behalf of:, Richard Warren, Lev Pavlovsky, Antonio Costanzo, Micahel Bukhalo, Neil J. Korman, Yu Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M Soliman, Simone Rubant, Diamant ThaciThe above Graphical Abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
